Management of Relapsed and Refractory Multiple Myeloma
Date: 25 February 2021 (Thursday)
Time: 19:15 - 20:40 (GMT+8, HKT)
Meeting format: Zoom meeting
Webinar on Management of Relapsed and Refractory Multiple Myeloma
Multiple myeloma (MM) is characterised by a monoclonal proliferation of plasma cells resulting in the production of monoclonal antibody and end-organ damage, whereas management of relapsed and refractory MM continues to be challenging. Nonetheless, the development of immunomodulatory drugs (IMiDs) in recent decades has significantly improved the outcomes of patients with relapsed and refractory MM. In the webinar titled “Management of Relapsed and Refractory Multiple Myeloma” organised by the Hong Kong Society of Myeloma on 25th February 2021, Prof. Meletios A. Dimopoulos of the School of Medicine, University of Athens shared the current updates on the roles of IMiDs in management of relapsed and refractory MM.
Prof. Dimopoulos presented the established clinical benefits of IMiDs in controlling relapsed and refractory MM. In particular, trial data suggested that lenalidomide-based therapy is effective in generating optimised complete response (CR) and very good partial response (VGPR) when used at first relapse regardless of the type of prior therapy, whereas continuous treatment with lenalidomide-based therapy would enhance quality of treatment response with preferable tolerability. Essentially, the beneficial effects of lenalidomide-based therapy were demonstrated in patients with various risk factors including aging and renal impairment. For the management of second relapse and beyond, Prof. Dimopoulos presented the promising treatment outcomes of pomalidomide-based therapies in lenalidomide refractory patients. The presentation was followed by a discussion session between Prof. Dimopoulos and local clinicians for exchanging clinical opinions in the management of relapsed and refractory MM.
Prof. Meletios A. Dimopoulos
Keynote Speaker
Prof. Chim Chor Sang, James
Chairperson of the webinar
Prof. Dimopoulos presented the efficacy of IMiDs in managing relapsed MM
Prof. James Chim (second right) and representatives of Bristol Myers Squibb
